Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2010: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2009: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2008: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
Research Abstract |
Accumulating evidence indicates that coronary vasoconstricting responses are enhanced at the edges of coronary segment implanted with drug-eluting stents (DES) compared with bare-metal stent (BMS) in humans. We have recently demonstrated that Rho-kinase pathway plays an important role in DES-induced coronary hyperconstricting responses in pigs in vivo and in patients with coronary artery diseases. Also, chronic treatment with long-acting nifedipine suppresses DES-induced coronary hyperconstricting responses and inflammatory changes, at least in part, through Rho-kinase pathway inhibition in pigs in vivo.
|